Anti-PD-L1

Where the papers sit

24 papers from the last 6 months study Anti-PD-L1 directly · updated from PubMed 12 Oct 2026

• Tumor Immune Microenvironment

  Immune-suppressive tumor microenvironments are being reprogrammed to improve anti-PD-L1 responses across cancers. Approaches target PD-L1 turnover with ethoxzolamide or selenium inhibitors, while USP5-FOXM1-Nectin2 signaling marks resistance. Other studies alter myeloid inflammation, T-cell niches, adenosine and cuproptosis, or use vaccines and bacteria. The direction is combination immunotherapy, although the varied models leave the most transferable strategy unresolved.

  12 papers · 50%

• Triple-Negative Breast Cancer Immunotherapy

  Triple-negative breast cancer immunotherapy is moving toward multimodal combinations that pair checkpoint targeting with chemotherapy, photodynamic therapy, virotherapy or metabolic intervention. Cabazitaxel-verteporfin nanoparticles and engineered probiotics seek to intensify tumor killing alongside immune activation. Oncolytic adenovirus targeting Siglec-10, hypoxia-lactate-calcium coupling and PD-L1/VEGF bispecific blockade extend this strategy. Peripheral immune dynamics may help distinguish effective chemoimmunotherapy from nonresponse.

  6 papers · 25%

• Colorectal Cancer Immunotherapy

  Colorectal cancer studies are shifting checkpoint blockade toward combinations that alter tumor metabolism, mechanics, microbiota and protein trafficking. Gemcitabine enhances anti-PD-L1 sensitivity through lactylation, while Faecalibacterium prausnitzii reprograms PD-L1 trafficking. Biomimetic nanodecoys address the mechano-immune microenvironment, and engineered bacteria combine tumor-targeted protein degradation with checkpoint inhibition. These preclinical sensitization strategies still require evidence for durability and clinical translation.

  4 papers · 16.7%

• Oral Cancer Immune Signaling

  CIP2A silencing is being paired with PD-1 macrophage nanoplatforms to activate immunity in oral squamous cell carcinoma. The same disease context includes PD-L1 profiling in potentially malignant disorders and tumor-free surgical margins. TCGA-linked analyses may clarify whether CIP2A and PD-L1 mark progression risk. The work is moving from biomarker description toward targeted immune remodeling, but clinical relevance remains open.

  2 papers · 8.3%